Merck Stock Worth Watching on PAH Drug Winrevair's Approval in Europe?Zacks Investment Research • 08/27/24
Merck Announces Phase 3 Trial Initiation for Bomedemstat, an Investigational Candidate for the Treatment of Certain Patients With Essential ThrombocythemiaBusiness Wire • 08/27/24
The Zacks Analyst Blog Costco, Merck & Co., Linde, Hamilton Beach Brands and Armanino Foods of DistinctionZacks Investment Research • 08/26/24
Merck Receives European Commission Approval for WINREVAIR™ (sotatercept) in Combination With Other Pulmonary Arterial Hypertension (PAH) Therapies, for the Treatment of PAH in Adult Patients With Functional Class II-IIIBusiness Wire • 08/26/24
Medicare Slashes Merck, Novo, AstraZeneca Drug Prices Up To 79% In IRA NegotiationsInvestors Business Daily • 08/15/24
Merck's Weakness Could Mean Profits With This Bearish Option TradeInvestors Business Daily • 08/14/24
Merck's $1.3B Deal For Potential Autoimmune Disorder Candidate Is Relevant To Cullinan's Investigational Drug, Says AnalystBenzinga • 08/09/24
Merck to buy experimental drug targeting B-cell diseases for up to $1.3 billionMarket Watch • 08/09/24
Merck to Acquire Investigational B-Cell Depletion Therapy, CN201, from Curon BiopharmaceuticalBusiness Wire • 08/09/24
Merck says it's discontinuing a late-stage trial of a lung cancer treatment after high number of adverse eventsMarket Watch • 08/08/24
Merck Provides Update on Phase 3 KeyVibe-008 Trial Evaluating an Investigational Fixed-Dose Combination of Vibostolimab and Pembrolizumab in Patients With Extensive-Stage Small Cell Lung CancerBusiness Wire • 08/08/24